Literature DB >> 187701

Effect of selective complement deficiency on the rate of neutralization of enveloped viruses by human sera.

J P Leddy, R L Simons, R G Douglas.   

Abstract

The capacity of human sera genetically deficient in selective complement (C) components to enhance neutralization of enveloped viruses was examined by kinetic plaque reduction assays. Vaccinia virus, a DNA virus, and vesicular stomatitis virus (VSV), an RNA virus, were studied. Exogenous rabbit: or human antibody to vaccinia virus, and guinea pig or human antibody to VSV were provided in limiting, C-dependent concentrations. IgG antibodies predominated in most of the antisera employed. C5-deficient and C6-deficient human sera consistently supported normal rates of neutralization of either virus; this effect was heat-labile. C4-deficient human serum did hot exceed heat-inactivated serum in any neutralization assay. C1r-deficient serum displayed slight heat-labile neutralizing capacity against vaccinia but none against VSV. C2- and C3-deficient sera consistently exhibited measurable but clearly subnormal rates of neutralization. Two fresh agammaglobulinemic sera failed to inactivate either virus in the absence of added antibody. These results confirm and extend earlier evidence, based on neutralization of herpes simplex and Newcastle disease viruses in the presence of early (IgM) antibody and functionally pure guinea pig C components or C-deficient animal sera, that the late-acting components C5-C9 are not required for C-dependent neutralization. Data on four enveloped viruses now agree that this function is mediated by C1-C3, although C1 plus C4 appear to have some neutralizing capacity. This requirement for C1-C3 is overcome, however, in the presence of higher antibody cohcentrations, suggesting that the contribution of the C system to viral neutralization in vivo may be chiefly in the early phase of infection when antibody is limited.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 187701

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  Complement in respiratory immunopathology.

Authors:  C Molina; J Brun; D Wahl
Journal:  Lung       Date:  1979       Impact factor: 2.584

2.  Complement requirement for virus neutralization by antibody and reduced serum complement levels associated with experimental equine herpesvirus 1 infection.

Authors:  D B Snyder; A C Myrup; S K Dutta
Journal:  Infect Immun       Date:  1981-02       Impact factor: 3.441

Review 3.  The complement system: its importance in the host response to viral infection.

Authors:  R L Hirsch
Journal:  Microbiol Rev       Date:  1982-03

Review 4.  Smallpox vaccines: targets of protective immunity.

Authors:  Bernard Moss
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

5.  Neutralization of Epstein-Barr virus by nonimmune human serum. Role of cross-reacting antibody to herpes simplex virus and complement.

Authors:  G R Nemerow; F C Jensen; N R Cooper
Journal:  J Clin Invest       Date:  1982-11       Impact factor: 14.808

Review 6.  Poxvirus pathogenesis.

Authors:  R M Buller; G J Palumbo
Journal:  Microbiol Rev       Date:  1991-03

7.  Genetic deficiency of C4, C2 or C1q and lupus syndromes. Association with anti-Ro (SS-A) antibodies.

Authors:  O Meyer; G Hauptmann; G Tappeiner; H D Ochs; F Mascart-Lemone
Journal:  Clin Exp Immunol       Date:  1985-12       Impact factor: 4.330

8.  Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence.

Authors:  S N Isaacs; G J Kotwal; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-15       Impact factor: 11.205

9.  Relation of gene expression (allotypes) of the fourth component of complement to insulin dependent diabetes and its microangiopathic complications.

Authors:  C Mijovic; J Fletcher; A R Bradwell; T Harvey; A H Barnett
Journal:  Br Med J (Clin Res Ed)       Date:  1985-07-06

10.  Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement.

Authors:  Mohammed Rafii-El-Idrissi Benhnia; Megan M McCausland; Juan Moyron; John Laudenslager; Steven Granger; Sandra Rickert; Lilia Koriazova; Ralph Kubo; Shinichiro Kato; Shane Crotty
Journal:  J Virol       Date:  2008-11-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.